MX2010008109A - Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv). - Google Patents

Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).

Info

Publication number
MX2010008109A
MX2010008109A MX2010008109A MX2010008109A MX2010008109A MX 2010008109 A MX2010008109 A MX 2010008109A MX 2010008109 A MX2010008109 A MX 2010008109A MX 2010008109 A MX2010008109 A MX 2010008109A MX 2010008109 A MX2010008109 A MX 2010008109A
Authority
MX
Mexico
Prior art keywords
present
compounds
serine protease
difluorinated
tripeptides
Prior art date
Application number
MX2010008109A
Other languages
English (en)
Inventor
Yat Sun Or
Zhe Wang
Yonghua Gai
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of MX2010008109A publication Critical patent/MX2010008109A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Abstract

La presente invención se refiere a compuestos de la Fórmula I, o una sal farmacéuticamente aceptable, éster, o profármaco de los mismos, los cuales inhiben la actividad de serina proteasa, particularmente la actividad de proteasa NS3-NS4A de virus de hepatitis C (HCV). consecuentemente, los compuestos de la presente invención interfieren con el ciclo de vida del virus de hepatitis C y también son útiles como agentes antivirales. La presente invención además se refiere a composiciones farmacéuticas que comprenden los compuestos antes mencionados para administrarse a un sujeto que sufre de una infección por HCV. La invención también se refiere a métodos para el tratamiento de una infección por HCV en un sujeto, administrando una composición farmacéutica que comprende los compuestos de la presente invención.
MX2010008109A 2008-01-24 2009-01-22 Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv). MX2010008109A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2324508P 2008-01-24 2008-01-24
PCT/US2009/031684 WO2009094443A1 (en) 2008-01-24 2009-01-22 Difluorinated tripeptides as hcv serine protease inhibitors

Publications (1)

Publication Number Publication Date
MX2010008109A true MX2010008109A (es) 2010-09-22

Family

ID=40901428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008109A MX2010008109A (es) 2008-01-24 2009-01-22 Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).

Country Status (7)

Country Link
US (1) US8501682B2 (es)
EP (1) EP2245015A4 (es)
JP (1) JP2011510927A (es)
CN (1) CN102036966A (es)
CA (1) CA2713005A1 (es)
MX (1) MX2010008109A (es)
WO (1) WO2009094443A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009070689A1 (en) * 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease
US8361958B2 (en) 2007-12-05 2013-01-29 Enanta Pharmaceuticals, Inc. Oximyl HCV serine protease inhibitors
CA2719008A1 (en) * 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
US8211891B2 (en) * 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
WO2012092409A2 (en) * 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
PT2909205T (pt) 2012-10-19 2017-02-06 Bristol Myers Squibb Co Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2- a)(1,4)diazaciclopentadecinilo substituídos com 9-metilo como inibidores da protease não estrutural 3 (ns3) para o tratamento de infeções por vírus da hepatite c
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
CA2902569A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Inhibitors of hepatitis c virus
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
US7273851B2 (en) 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
MY148123A (en) * 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20080197A1 (es) 2006-02-09 2008-04-11 Schering Corp Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s)
UY30437A1 (es) 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7582605B2 (en) 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
JP5529036B2 (ja) 2007-12-05 2014-06-25 エナンタ ファーマシューティカルズ インコーポレイテッド フッ素化トリペプチドｈｃｖセリンプロテアーゼ阻害剤
US8361958B2 (en) 2007-12-05 2013-01-29 Enanta Pharmaceuticals, Inc. Oximyl HCV serine protease inhibitors
CA2719008A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors

Also Published As

Publication number Publication date
US8501682B2 (en) 2013-08-06
JP2011510927A (ja) 2011-04-07
US20090202486A1 (en) 2009-08-13
EP2245015A1 (en) 2010-11-03
CA2713005A1 (en) 2009-07-30
EP2245015A4 (en) 2012-05-30
CN102036966A (zh) 2011-04-27
WO2009094443A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
MX2010006210A (es) Inhibidores de serina proteasa de hcv de tripeptido fluorado.
MX2010008109A (es) Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).
MY155851A (en) Quinoxaline-containing compounds as hepatitis c virus inhibitors
MX2019013037A (es) Prolina macrociclica derivada de inhibidores de serina proteasa de vhc.
MX2010006209A (es) Derivados de quinoxalinilo.
MX2010010276A (es) Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c.
MX2010006518A (es) Inhibidores de serina proteasa de hepatitis c de oximil macrociclica.
MX2010005261A (es) Inhibidores macrocíclicos de proteasa de serina de hepatitis c de tetrazolilo.
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
MX2011012155A (es) Compuestos macrociclicos como inhibidores del virus de hepatitis c.
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
WO2009076166A3 (en) Oximyl hcv serine protease inhibitors
WO2008022006A3 (en) Arylalkoxyl hepatitis c virus protease inhibitors
WO2008002924A3 (en) Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
WO2007143694A3 (en) Macrocyclic oximyl hepatitis c protease inhibitors
WO2008021960A3 (en) Triazolyl macrocyclic hepatitis c serine protease inhibitors
WO2008021956A3 (en) Acylaminoheteroaryl hepatitis c virus protease inhibitors
WO2008021733A3 (en) Tetrazolyl acyclic hepatitis c serine protease inhibitors
WO2008019303A3 (en) Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
WO2008019289A3 (en) Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
MX2010008108A (es) Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo.
TN2012000358A1 (en) Hepatitis c virus inhibitors
WO2011049908A3 (en) Bismacrokyclic compounds as hepatitis c virus inhibitors
EP2555622A4 (en) HEPATITIS C-VIRUS HEMMER

Legal Events

Date Code Title Description
FA Abandonment or withdrawal